Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and…
| Métrica | BBTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 58.3% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.9% | — |
| FCF Margin | — | -10.6% | — |
| ROE | — | -36.3% | — |
| ROA | — | -29.8% | — |
| Current Ratio | — | 2.68 | — |
| Debt / Equity | — | 0.28 | — |
Bambusa Therapeutics, Inc. cotiza a 16.75 USD y tiene una capitalización bursátil de $853M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud